-Reuters
Reported Sunday, AstraZeneca And Amgen’s TEZSPIRE Shows Potential For Future Chronic Obstructive Pulmonary Diseasetreatment In New Data Presented At ATS 2024
Late-breaking results from the Phase IIa COURSE trial provide insight into TEZSPIRE's impact on COPD exacerbations in patients with a broad range of eosinophil levels
The Phase IIa COURSE trial was a